Treatment of Candida albicans Infections

Introduction to Treatment

The Infectious Diseases Society of America recommends fluconazole as the preferred first-line therapy for Candida albicans infections, with dosing and duration dependent on infection site and severity 1

For invasive C. albicans infections, the Infectious Diseases Society of America recommends fluconazole 400 mg daily as appropriate first-line therapy in non-critically ill patients with documented susceptible isolates 2, 1
In critically ill patients, the Infectious Diseases Society of America suggests initiating treatment with an echinocandin rather than fluconazole, then de-escalating to fluconazole once the patient stabilizes and susceptibility is confirmed 2, 1
The Infectious Diseases Society of America recommends continuing treatment for at least 14 days after documented clearance of Candida from bloodstream and resolution of symptoms 1, 3
The Infectious Diseases Society of America advises removing all central venous catheters whenever feasible, as this significantly improves outcomes 1, 3

The Infectious Diseases Society of America recommends treating esophageal candidiasis with fluconazole 100 mg daily for 14-21 days 4
The Infectious Diseases Society of America suggests that fluconazole and itraconazole solution are both highly effective, though fluconazole is preferred due to superior tolerability 5, 4

The Infectious Diseases Society of America recommends a single dose of oral fluconazole 150 mg for uncomplicated vulvovaginal candidiasis, which is as effective as topical azole therapy 4
The Infectious Diseases Society of America advises that uncomplicated VVC responds to short-course therapy, either single-dose oral fluconazole 150 mg or topical azoles for 1-7 days 4
The Infectious Diseases Society of America recommends extended therapy for >7 days for complicated VVC, and maintenance fluconazole 150 mg weekly for 6 months for recurrent VVC 4, 5

The Infectious Diseases Society of America recommends initiating liposomal amphotericin B 5 mg/kg daily, with or without oral flucytosine 25 mg/kg four times daily, for CNS candidiasis 1
The Infectious Diseases Society of America suggests adding flucytosine for synergistic activity and excellent CSF penetration, but monitoring serum levels, liver function, and bone marrow closely due to toxicity 1

The Infectious Diseases Society of America recommends fluconazole 12 mg/kg daily for neonates with disseminated candidiasis if C. albicans is isolated 2, 3
The Infectious Diseases Society of America suggests that fluconazole 400 mg daily is appropriate for prophylaxis during neutropenia in high-risk patients 4

The Infectious Diseases Society of America recommends standard fluconazole dosing for invasive infections as 400 mg (6 mg/kg) daily, but increasing to 800 mg (12 mg/kg) daily for severe infections or to ensure adequate drug levels 1, 3
The Infectious Diseases Society of America advises reducing the dose in renal impairment based on creatinine clearance 1

The Infectious Diseases Society of America recommends obtaining cultures and susceptibility testing before finalizing therapy 2, 1
The Infectious Diseases Society of America suggests that antifungal susceptibility testing at vaginal pH 4 reveals clinically relevant resistance that may contribute to treatment failure 5

The Infectious Diseases Society of America recommends treating candidemia for at least 14 days after blood culture clearance and symptom resolution, and deep-seated infections require longer courses until all clinical, laboratory, and radiographic abnormalities resolve 1, 3
The Infectious Diseases Society of America advises treatment durations of 14-21 days for esophageal candidiasis, single dose or 1-7 days for uncomplicated VVC, >7 days for complicated VVC, 6 months for recurrent VVC maintenance, and weeks to months based on response for CNS infections 4, 5, 1